Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 May 14

PMID 35566517

Authors

Hyunji Jo

Sojung Park

Nam Eun Kim

So Young Park

Yon Ju Ryu

Jung Hyun Chang

Jin Hwa Lee

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among 221 patients with advanced NSCLC and COPD, 124 patients received treatment for COPD and 97 patients did not receive treatment for COPD. Forced expiratory volume in 1 s (FEV1) % predicted value was greater in the no-treatment group than in the COPD treatment group (p < 0.001). The median overall survival (OS) of the treatment group was 10.7 months, while that of the no-treatment group was 8.7 months (p = 0.007). In the multivariate analysis, COPD treatment was independently associated with improved OS (hazard ratio 0.71, 95% confidence interval 0.53−0.95, and p = 0.021). COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.

Citing Articles

Diagnosis and management of comorbid disease in COPD.

Cronin E, Cushen B Breathe (Sheff). 2025; 21(1):240099.

PMID: 40007528 PMC: 11851148. DOI: 10.1183/20734735.0099-2024.

Impact of Triple Inhaler Therapy on COPD Patients with Non-Small Cell Lung Cancer After Radical Surgery: A Single-Centre Retrospective Analysis.

Bertuccio F, DAgnano V, Cordoni S, Tafa M, Novy C, Baio N J Clin Med. 2025; 14(1.

PMID: 39797331 PMC: 11722558. DOI: 10.3390/jcm14010249.

Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII).

Zhong C, Chen E, Su Z, Chen D, Wang F, Wang X Respirology. 2024; 30(1):51-61.

PMID: 39197870 PMC: 11688625. DOI: 10.1111/resp.14822.

Impact of COPD pulmonary structural remodeling on the prognosis of patients with advanced lung squamous cell carcinoma.

Gao X, Wang Z, Liu J, Fan J, Huang K, Han Y Heliyon. 2023; 9(11):e22042.

PMID: 38027974 PMC: 10665830. DOI: 10.1016/j.heliyon.2023.e22042.

Prevalence, diagnosis, and treatment of chronic obstructive pulmonary disease in a hospitalized lung cancer population: a single center study.

Qu H, Zhu M, Shan C, Ji X, Ji G, Zhang W J Thorac Dis. 2023; 15(8):4182-4197.

PMID: 37691644 PMC: 10482625. DOI: 10.21037/jtd-23-267.

References

Bolukbas S, Eberlein M, Eckhoff J, Schirren J . Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial. Eur J Cardiothorac Surg. 2010; 39(6):995-1000. DOI: 10.1016/j.ejcts.2010.09.025. View

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

Simmons C, Koinis F, Fallon M, Fearon K, Bowden J, Solheim T . Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors. Lung Cancer. 2015; 88(3):304-9. DOI: 10.1016/j.lungcan.2015.03.020. View

Patil S, Krishnan J, Lechtzin N, Diette G . In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003; 163(10):1180-6. DOI: 10.1001/archinte.163.10.1180. View

Lipson D, Barnhart F, Brealey N, Brooks J, Criner G, Day N . Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018; 378(18):1671-1680. DOI: 10.1056/NEJMoa1713901. View

Semrau S, Klautke G, Virchow J, Kundt G, Fietkau R . Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med. 2007; 102(2):210-8. DOI: 10.1016/j.rmed.2007.09.009. View

Lee S, Choi Y, Seo J, Yong Lee S, Kim J, Joo Kang E . Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer. J Thorac Dis. 2020; 11(11):4562-4572. PMC: 6940228. DOI: 10.21037/jtd.2019.10.77. View

Malo de Molina R, Mortensen E, Restrepo M, Copeland L, Pugh M, Anzueto A . Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J. 2010; 36(4):751-7. DOI: 10.1183/09031936.00077509. View

Rabe K, Martinez F, Ferguson G, Wang C, Singh D, Wedzicha J . Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020; 383(1):35-48. DOI: 10.1056/NEJMoa1916046. View

10.

Celli B, Cote C, Marin J, Casanova C, Montes de Oca M, Mendez R . The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(10):1005-12. DOI: 10.1056/NEJMoa021322. View

11.

Lim J, Yeo C, Rhee C, Kang H, Park C, Kim J . Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients. Int J Chron Obstruct Pulmon Dis. 2019; 14:929-938. PMC: 6503336. DOI: 10.2147/COPD.S190244. View

12.

Chen D, Restrepo M, Fine M, Pugh M, Anzueto A, Metersky M . Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med. 2011; 184(3):312-6. PMC: 3175534. DOI: 10.1164/rccm.201012-2070OC. View

13.

Greillier L, Thomas P, Loundou A, Doddoli C, Badier M, Auquier P . Pulmonary function tests as a predictor of quantitative and qualitative outcomes after thoracic surgery for lung cancer. Clin Lung Cancer. 2008; 8(9):554-61. DOI: 10.3816/CLC.2007.n.042. View

14.

Duong M, Islam S, Rangarajan S, Leong D, Kurmi O, Teo K . Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV (PURE): an international, community-based cohort study. Lancet Glob Health. 2019; 7(5):e613-e623. DOI: 10.1016/S2214-109X(19)30070-1. View

15.

Parron Collar D, Pazos Guerra M, Rodriguez P, Gotera C, Mahillo-Fernandez I, Peces-Barba G . COPD is commonly underdiagnosed in patients with lung cancer: results from the RECOIL study (retrospective study of COPD infradiagnosis in lung cancer). Int J Chron Obstruct Pulmon Dis. 2017; 12:1033-1038. PMC: 5383077. DOI: 10.2147/COPD.S123426. View

16.

Kobayashi S, Suzuki S, Niikawa H, Sugawara T, Yanai M . Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology. 2009; 14(5):675-9. DOI: 10.1111/j.1440-1843.2009.01543.x. View

17.

Makino T, Otsuka H, Hata Y, Koezuka S, Azuma Y, Isobe K . Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery. Mol Clin Oncol. 2018; 8(5):647-652. PMC: 5920355. DOI: 10.3892/mco.2018.1595. View

18.

Lee Y, Kim S, Lee J, Ha E . Inhaled corticosteroids in COPD and the risk of lung cancer. Int J Cancer. 2018; 143(9):2311-2318. DOI: 10.1002/ijc.31632. View

19.

Win T, Jackson A, Sharples L, Groves A, Wells F, Ritchie A . Relationship between pulmonary function and lung cancer surgical outcome. Eur Respir J. 2005; 25(4):594-9. DOI: 10.1183/09031936.05.00077504. View

20.

Zhai R, Yu X, Shafer A, Wain J, Christiani D . The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest. 2013; 145(2):346-353. PMC: 3913301. DOI: 10.1378/chest.13-1176. View